Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

Massachusetts General Hospital · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06003153

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
125
US sites recruiting
1
Study start
March 12, 2024
Record last updated
July 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a standardized breakfast meal at the first visit and after taking 14 doses of oral semaglutide over two weeks before the second study visit. The food (mixed meal breakfast) we will be studying is specially prepared to contain a set amount of protein, carbohydrates, and fat. The investigators hypothesize that understanding how the acute biochemical response to oral semaglutide differs by genetic variation will generate insight into drug mechanisms and type 2 diabetes pathophysiology.

Being studied: oral semaglutide; Mixed Meal Tolerance Test (MMTT)

Conditions: Genetic Predisposition; Metabolic Diseases; Type 2 Diabetes

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Males or non-pregnant females
  • Ages 18-65 (inclusive)
  • Able/willing to give consent
  • Span the metabolic range between normal glycemia and pre-diabetes (fasting glucose of 100-125 mg/dL based on chart review of existing laboratory data)

Exclusion Criteria

  • Currently taking medications or intending to take medications for diabetes
  • Currently taking medications or intending to take medications that affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones
  • Personal history of intestinal malabsorption, bariatric surgery, celiac disease, gallbladder disease, or pancreatitis
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
  • Estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2 per the Modification of Diet in Renal Disease equation
  • History of cirrhosis and/or aspartate aminotransferase or alanine aminotransferase more than 3x upper limit of normal
  • Dietary restrictions preventing consumption of a MMTT
  • Women who are pregnant, nursing, or at risk of becoming pregnant
  • Participation in other interventional studies during the current study

Recruiting US locations

  • Massachusetts General Hospital

    Boston, MA 02114

    Site contact: Varinderpal Kaur · 6176435419 · vkaur@mgh.harvard.edu

Study contacts (from the official record)

  • Varinderpal Kaur · 6176435419 · vkaur@mgh.harvard.edu
  • Josephine Li · 617-643-4987 · jli71@mgh.harvard.edu
All diabetes studies in Massachusetts →
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral… (NCT06003153) | Bored Studies